2022 Fiscal Year Final Research Report
Development of a novel quantitative biomarter for intrauterine microorganisms and treatment flowchart to prevent severe compication in preterm infants.
Project/Area Number |
20K09663
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 56040:Obstetrics and gynecology-related
|
Research Institution | University of Toyama |
Principal Investigator |
YONEDA NORIKO 富山大学, 学術研究部医学系, 助教 (80377283)
|
Co-Investigator(Kenkyū-buntansha) |
仁井見 英樹 富山大学, 学術研究部医学系, 准教授 (50401865)
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | 早産 / 子宮内感染・炎症 / 起炎菌同定・定量検査法 / 早産児の長期神経発達 / 国際比較 |
Outline of Final Research Achievements |
We have developed a rapid, highly sensitive PCR for intrauterine microorganisms in preterm labor patient and have reported the poor prognosis of superinfection and the effectiveness of appropriate antiniotic therapy. In this study, we established a new system to identify and evaluate bacterial species. We found that cases with high amniotic fluid bacteria levels in cases of preterm labor had a high rate of superinfection and neonatal infections, and had a poor perinatal prognosis. The long-term neurodevelopmental prognosis of preterm infants was evaluated using the Bayley Infant Development Scale, and we reported that the poor neurodevelopmental prognostic factors were preterm delivery at less than 30 weeks' gestation and preeclampsia with decreased maternal renal function. In collaboration with McMaster University in Canada, we also conducted an international comparison of preterm birth management in Japan and Canada and reported the strengths of the two countries.
|
Free Research Field |
産婦人科
|
Academic Significance and Societal Importance of the Research Achievements |
日本の超低出生体重児(出生体重1000g未満)の予後は、3歳までの死亡率約15%、神経学的後遺症、視力障害、呼吸器疾患などの重篤な障害をもつ割合は約30%とされ、長期間のNICU入院が必要であり、退院後も重い障害をもった児をケアできる施設が極めて限られているという問題もある。本研究の成果により、切迫早産の子宮内病原微生物を迅速高感度に検出定量することができ、適切な抗菌薬投与が可能となるため、学術的意義がある。また、菌量をバイオマーカーとした治療効果判定、より適切な治療薬の選択による早産児の重症化予防が期待される。ひいては、早産児の予後改善につながり社会的意義があると考えられる。
|